Yesterday, the Government of Alberta announced guidelines for psychedelic assisted therapy, beginning in 2023. This makes Alberta the first province in Canada to provide a pathway for the use of psychedelic drugs for medical usage.

As the home province of Diplomat, we are proud to be situated in an area with progressive foresight on medically assisted therapies, and see this new therapeutic framework as one to be celebrated. Mental health and addiction issues, especially those who experience treatment resistance, can celebrate the ability to utilize these therapies in a safe and standardized manner in the presence of trained medical professionals.

This new regulation will include the use of: psilocybin, psilocin, MDMA, LSD, mescaline, DMT, and ketamine. Psychedelic assisted therapy – or psychotherapy – has been research for decades, with calls for increased access and usage for several years.

As a team of professionals that provide regulatory foresight for economic opportunity, we are here to offer assistance and guidance on framework development. Reach out to use to discuss how this can benefit, and be incorporated into, your business. From psilocybin companies, pharmacies, to musical clinics, Alberta has presented us all with a globally unique opportunity to pioneer psychotherapy in a commercialized and regulated environment. Let us help you ensure your business is part of this one-of-a-kind development.

With the proper framework surrounding this, we see a promising future for the implementation of a new pathway of medical treatment around mental health and addiction issues.